Combined oxidative phosphorylation deficiency (often shortened to COXPD) is a group of very rare, inherited mitochondrial diseases. In this condition, several of the energy-making “machines” (called respiratory chain complexes I–V) inside the mitochondria do not work properly at the same time. This makes it hard for cells to produce enough energy. Organs that need a lot of energy, such as the brain, liver, heart, and muscles, are usually affected the most. In COXPD, the problem usually comes from a change (mutation) in a gene located in the cell nucleus or in mitochondrial DNA. These genes normally help build or control the oxidative phosphorylation (OXPHOS) system. When the genes are faulty, the mitochondria cannot make energy efficiently from food, and lactic acid and other substances can build up. This can cause symptoms like developmental delay, low or high muscle tone, seizures, liver disease, heart problems, and early death in severe cases.
Combined oxidative phosphorylation deficiency (COXPD) is a group of rare, inherited mitochondrial diseases. In this condition, several parts of the mitochondrial respiratory chain (complex I–V) do not work properly, so cells cannot make enough adenosine triphosphate (ATP), the main energy molecule in the body. This energy failure especially affects organs that need a lot of energy, such as the brain, muscles, heart, liver, and sometimes kidneys. Children often present with developmental delay, weak muscle tone, feeding problems, seizures, lactic acidosis, and sometimes heart or liver failure. Many subtypes are known (COXPD1–COXPD51), each linked to different genes, but the result is similar: serious multi-system disease and high medical needs. 1 2
COXPD is usually inherited in an autosomal recessive way. This means a child gets one non-working copy of the gene from each parent, who are usually healthy carriers. Many different genes can cause different numbered types, and more than 50 COXPD subtypes (COXPD1–COXPD51) have already been reported.
Other names
Doctors and researchers may use several other names for combined oxidative phosphorylation deficiency. These names often describe specific subtypes or focus on the main organs involved:
-
Combined oxidative phosphorylation defect
-
Combined oxidative phosphorylation deficiency type 1, 2, 3… (COXPD1, COXPD2, etc.)
-
Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 (for COXPD1 with mainly liver and brain involvement)
-
MTO1-combined oxidative phosphorylation deficiency (for some heart-dominant forms)
-
Early fatal progressive hepatoencephalopathy due to COXPD1
-
Mitochondrial oxidative phosphorylation disorder due to nuclear gene defects
These names all describe diseases where more than one oxidative phosphorylation complex is impaired at the same time.
Types
There is not just one single disease called COXPD. Instead, there are many numbered types (for example, COXPD1, COXPD10, COXPD20, COXPD31). Each type is linked to changes in a different gene, and the main symptoms may be slightly different. However, they all share the common feature of reduced function in several OXPHOS complexes.
Some examples of COXPD types include:
-
COXPD1 (GFM1-related) – Often causes severe liver and brain disease (hepatoencephalopathy), failure to thrive, lactic acidosis, and early death in infancy or early childhood.
-
COXPD10 (MTO1-related) – Usually presents with hypertrophic cardiomyopathy (thickened heart muscle), lactic acidosis, and sometimes neurologic problems.
-
COXPD12 (EARS2-related) – Often shows lactic acidosis, hypotonia, developmental delay, and sometimes characteristic brain MRI findings such as leukoencephalopathy.
-
COXPD17 (ELAC2-related) – Very rare; can cause developmental delay, hypotonia, seizures, and other neurologic features.
-
COXPD18 (SFXN4-related) – May cause growth restriction, lactic acidosis, vision problems, and speech delay.
-
COXPD20 (VARS2-related) – Often presents with psychomotor delay, hypotonia, seizures, microcephaly, cardiomyopathy, and mild facial differences.
-
COXPD22 (ATP5A1/ATP5F1A-related) – Can cause growth restriction, microcephaly, pulmonary hypertension, heart failure, and severe neurologic problems.
-
COXPD29, 31, 37 and others – These types can show microcephaly, severe developmental delay, seizures, optic atrophy, cardiomyopathy, and progressive brain atrophy, depending on the affected gene.
Even though the specific types differ, they all involve a combined deficiency of multiple respiratory chain complexes and typically follow an autosomal recessive inheritance pattern.
Causes of combined oxidative phosphorylation deficiency
1. Mutations in GFM1 gene
One main cause of COXPD1 is mutation in the GFM1 gene, which makes a protein needed for mitochondrial protein translation (mitochondrial elongation factor G1). If this protein does not work, fewer OXPHOS proteins are made, and several complexes become weak.
2. Mutations in FARS2 gene
Changes in FARS2, which encodes mitochondrial phenylalanyl-tRNA synthetase, can lead to COXPD14. This enzyme helps attach the amino acid phenylalanine to its tRNA in mitochondria. When it fails, many mitochondrial proteins are not built correctly, and multiple respiratory complexes are affected.
3. Mutations in VARS2 gene
Pathogenic variants in VARS2 cause COXPD20. VARS2 encodes mitochondrial valyl-tRNA synthetase. When this enzyme is defective, the cell cannot properly translate many mitochondrial proteins, leading to combined deficiencies of complexes I, III, IV, and V and causing severe neurologic and cardiac symptoms.
4. Mutations in FASTKD2 gene
FASTKD2-related COXPD affects a protein that helps process mitochondrial RNA. Abnormal FASTKD2 disrupts the production of several OXPHOS proteins, causing developmental regression, seizures, movement disorders, and stroke-like episodes in some patients.
5. Mutations in ELAC2 gene
ELAC2 is important for cutting (processing) mitochondrial tRNA. Mutations in ELAC2 lead to COXPD17. Faulty tRNA processing means many mitochondrial proteins cannot be made correctly, so multiple complexes are underactive and cells cannot meet their energy needs.
6. Mutations in SFXN4 gene
The SFXN4 gene encodes a mitochondrial inner membrane protein involved in iron–sulfur cluster biogenesis and electron transport. Mutations in SFXN4 cause COXPD18, with reduced activity of several respiratory complexes and lactic acidosis.
7. Mutations in RMND1 gene
RMND1 helps anchor the mitochondrial translation system to the inner membrane. Mutations cause COXPD11 with neonatal hypotonia, lactic acidosis, and early death. Poor translation of multiple mitochondrial proteins lowers the function of more than one complex.
8. Mutations in MTO1 gene
MTO1 is needed for proper modification of mitochondrial tRNAs. MTO1 mutations can cause a form of combined oxidative phosphorylation deficiency with hypertrophic cardiomyopathy and lactic acidosis. This again blocks the normal production of multiple OXPHOS subunits.
9. Mutations in ATP5A1 / ATP5F1A gene
ATP5A1 (also known as ATP5F1A) encodes a subunit of complex V (ATP synthase). Mutations cause COXPD22, but because complex V interacts with other complexes and the inner membrane, these changes can disturb the whole OXPHOS system.
10. Mutations in MIPEP gene
MIPEP encodes a mitochondrial peptidase that helps process newly made proteins. Mutations can cause COXPD31, with global developmental delay and heart muscle abnormalities. When MIPEP does not work, many respiratory chain proteins stay immature and non-functional.
11. Mutations in MRPS2 and other mitochondrial ribosomal proteins
Genes like MRPS2 encode parts of the mitochondrial ribosome. Variants can lead to COXPD36 and similar types. When the ribosome is damaged, mitochondrial protein synthesis is globally reduced, and several complexes lose activity.
12. Mutations in MRPL49 and other large-subunit ribosomal proteins
MRPL49 is another ribosomal gene. Biallelic variants were found in families with combined oxidative phosphorylation deficiency and symptoms like leukodystrophy and hearing loss. Defects in such genes again disturb translation of many mitochondrial proteins at once
13. Mutations in mitochondrial translation factors (TSFM, TUFM and others)
Genes such as TSFM and TUFM, which encode mitochondrial translation factors, are also linked to COXPD subtypes. When these factors fail, the process of building mitochondrial proteins stalls, causing combined deficiencies of several complexes.
14. Mutations in tRNA processing genes besides ELAC2
Other genes that help cut or modify mitochondrial tRNAs can also cause COXPD. Any defect in these pathways means many mitochondrial proteins cannot be translated correctly, so the oxidative phosphorylation chain as a whole is weak.
15. Mutations causing mitochondrial DNA depletion
Some nuclear genes control the copying of mitochondrial DNA (mtDNA). If these genes are faulty, mtDNA becomes depleted. Because mtDNA carries many OXPHOS genes, low mtDNA levels cause reduced activity of several complexes together.
16. Mutations causing large mtDNA deletions
Large deletions in mtDNA can remove multiple genes for complexes I, III, IV, and V. This can present with a combined OXPHOS deficiency pattern rather than a problem in just one complex.
17. Mutations in assembly factors for respiratory chain complexes
Many nuclear genes help assemble complexes into correct shapes. When these assembly factors are defective, individual complexes cannot form or cannot join into “super-complexes.” This may lead to combined defects in multiple complexes.
18. Defects in mitochondrial protein import machinery
Some COXPD-like syndromes result from problems in proteins that import nuclear-encoded proteins into mitochondria. If import is poor, many OXPHOS components never reach their place in the inner membrane, lowering overall oxidative phosphorylation.
19. Coenzyme Q10 biosynthesis defects
Coenzyme Q10 (CoQ10) carries electrons between complexes I/II and III. When CoQ10 biosynthesis genes are mutated, the activities of several complexes are functionally reduced, giving a combined oxidative phosphorylation deficiency picture.
20. Still-unknown genetic causes
Even with modern sequencing, some people with clear combined complex deficiencies have no known gene mutation. In these families, the cause is likely a yet-undiscovered gene affecting mitochondrial protein synthesis, assembly, or maintenance.
Symptoms of combined oxidative phosphorylation deficiency
1. Developmental delay
Many children with COXPD learn to sit, stand, walk, or speak later than expected. Some may lose skills they had already gained (developmental regression). This happens because the brain, which needs a lot of energy, cannot function normally when oxidative phosphorylation is weak.
2. Failure to thrive and poor growth
Infants often have trouble gaining weight and growing in length or height. They may feed poorly, tire easily while feeding, or vomit frequently. The chronic lack of energy in many organs and frequent illness can limit normal growth.
3. Hypotonia (low muscle tone)
Many patients have “floppy” muscles, especially in the trunk (axial hypotonia). They may feel soft when held and have difficulty supporting the head or sitting. Low tone reflects poor energy production in muscles and motor pathways in the brain.
4. Hypertonia, spasticity, or abnormal movements
Some children later develop stiff muscles, spasticity (tightness), or dystonic and choreic movements. These abnormal movements come from damage to deep brain structures like the basal ganglia because of long-term energy failure.
5. Seizures
Epileptic seizures are common in many COXPD types. They may be focal or generalized and can be hard to control. Energy failure in the cortex and deep brain structures makes cells more likely to fire abnormally, leading to seizures.
6. Encephalopathy (brain dysfunction)
Children can show irritability, poor alertness, confusion, or coma. Brain imaging may reveal white matter loss or basal ganglia lesions. This encephalopathy reflects global energy shortage and lactic acidosis in the brain.
7. Microcephaly (small head size)
Some affected children have a head size much smaller than expected for age and sex. This can be present at birth or appear as the child grows, and it suggests reduced brain growth due to chronic mitochondrial dysfunction.
8. Peripheral neuropathy
Loss of feeling, weakness, or reduced reflexes in the arms and legs can occur. Nerve cells and long nerve fibers need constant energy, so they are vulnerable when oxidative phosphorylation fails, leading to neuropathy signs.
9. Liver dysfunction and liver failure
The liver may become enlarged or show high enzymes on blood tests, and in severe cases, liver failure can develop. The liver has very high energy needs, especially in newborns, so impaired OXPHOS can quickly damage liver cells.
10. Cardiomyopathy and heart failure
Some COXPD types cause thickened or weakened heart muscle. Children may develop heart failure with poor feeding, fast breathing, or poor circulation. The heart continuously needs energy, so mitochondrial defects often affect it.
11. Respiratory problems
Infants may have rapid breathing, low oxygen levels, or respiratory failure, sometimes due to muscle weakness or brainstem involvement. Lactic acidosis can also stimulate fast breathing as the body tries to blow off extra acid.
12. Lactic acidosis
Many patients show high levels of lactic acid in the blood and sometimes in cerebrospinal fluid. This happens because cells switch from efficient oxidative phosphorylation to less efficient glycolysis, which produces more lactate.
13. Visual problems and optic atrophy
Some COXPD types cause optic nerve damage, nystagmus, strabismus, or general visual impairment. The optic nerve has high metabolic needs, so energy failure can lead to progressive loss of vision.
14. Hearing loss
Sensorineural hearing loss may occur, especially in some ribosomal protein–related forms (for example MRPL49-related disease). Inner ear cells and auditory nerves need constant energy, so mitochondrial dysfunction can harm hearing.
15. Early death in severe forms
Sadly, many infants with the most severe forms of COXPD die in the first weeks or years of life because of combined brain, liver, heart, and respiratory failure. Prognosis depends on the specific gene, residual enzyme activity, and available supportive care.
Diagnostic tests for combined oxidative phosphorylation deficiency
Physical examination tests
1. General growth and developmental assessment
The doctor measures weight, length/height, and head size and compares them with age-based charts. They also ask about developmental milestones such as sitting, walking, and talking. Delayed milestones, poor growth, and microcephaly can suggest a serious metabolic or mitochondrial disease like COXPD.
2. Neurological examination
The clinician checks muscle tone, reflexes, strength, eye movements, and coordination. Findings such as axial hypotonia, limb spasticity, abnormal movements, or peripheral neuropathy give clues that the brain, spinal cord, or nerves are damaged by energy failure.
3. Cardiovascular examination
Listening to the heart and checking pulses, blood pressure, and signs of heart failure (such as swelling, enlarged liver, or breathing difficulty) are important. Cardiomyopathy or heart failure in a small child with lactic acidosis should raise suspicion of a mitochondrial disorder.
4. Abdominal and liver examination
The doctor gently feels the abdomen for an enlarged liver or spleen and looks for signs of liver failure, such as jaundice or fluid in the abdomen. These findings, combined with neurologic symptoms, point toward hepatoencephalopathy seen in COXPD.
Manual tests
5. Manual muscle strength testing
Using simple resistance (for example, pushing against the examiner’s hand), the doctor grades muscle strength. Weakness, especially along with hypotonia or fatigue, supports the idea of a mitochondrial myopathy as part of COXPD.
6. Gait and posture assessment
If the child can walk, the doctor watches how they move, turn, and stand. An unsteady gait, frequent falls, or difficulty rising from the floor may indicate muscle weakness, ataxia, or pyramidal signs from brain involvement.
7. Developmental and functional scales
Structured tools (for example, developmental scales or functional questionnaires) may be used to rate motor, speech, and cognitive abilities. Low scores or loss of previously gained skills suggest global encephalopathy and help track disease progression.
8. Manual assessment of fatigue and exercise tolerance
Doctors may ask older children to perform repeated simple tasks (such as stepping or gripping) and watch for rapid fatigue and recovery time. Quick exhaustion can point to impaired energy production in muscle and heart.
Laboratory and pathological tests
9. Blood lactate and pyruvate levels
Raised lactate, often together with an abnormal lactate-to-pyruvate ratio, is a hallmark clue of mitochondrial oxidative phosphorylation disorders. High lactate appears because cells switch from OXPHOS to glycolysis when the respiratory chain is impaired.
10. Blood gas and acid–base analysis
Arterial or capillary blood gases reveal metabolic acidosis from lactic acid build-up. Severe or persistent acidosis in a sick infant, especially with neurologic signs, suggests an inborn error of metabolism such as COXPD.
11. Liver function tests (LFTs)
Blood tests measuring enzymes (AST, ALT), bilirubin, and clotting factors help assess liver health. High enzymes or poor clotting in a child with neurologic problems and lactic acidosis support the diagnosis of hepatoencephalopathy due to COXPD.
12. Creatine kinase (CK) and muscle enzymes
CK may be mildly or moderately elevated if muscles are damaged. This is not specific but can support mitochondrial myopathy when combined with other findings like weakness and lactic acidosis.
13. Plasma amino acids and organic acids
These tests can show patterns suggesting mitochondrial dysfunction, such as elevated alanine and other markers of chronic lactic acidosis. They help rule out other metabolic conditions and support a mitochondrial diagnosis.
14. Muscle biopsy with respiratory chain enzyme assays
A small piece of muscle can be examined under the microscope and tested for respiratory chain enzyme activities. Reduced activity in more than one complex confirms a combined oxidative phosphorylation deficiency.
15. Genetic testing (targeted or exome/genome sequencing)
Sequencing can look for pathogenic variants in known COXPD genes (such as GFM1, FARS2, VARS2, FASTKD2, ELAC2, SFXN4, ATP5A1, MIPEP, and many others). Modern exome or genome sequencing often identifies the exact gene defect and COXPD type.
Electrodiagnostic tests
16. Electroencephalogram (EEG)
EEG records the brain’s electrical activity. In COXPD, it may show slowing or epileptic discharges that match the child’s seizures or encephalopathy. While not specific, EEG helps document the degree of brain involvement.
17. Electromyography (EMG)
EMG studies muscle and nerve function. In some patients, EMG can show signs of myopathy or neuropathy, supporting a mitochondrial neuromuscular disorder and guiding muscle biopsy decisions.
18. Nerve conduction studies (NCS)
NCS measure how quickly electrical signals travel along nerves. Slowed conduction or low amplitudes can confirm peripheral neuropathy, which is reported in some COXPD forms.
Imaging tests
19. Brain MRI
Magnetic resonance imaging of the brain often shows abnormalities in COXPD, such as white matter loss (leukodystrophy), basal ganglia lesions, cerebellar atrophy, or thinning of the corpus callosum. These patterns, combined with lactic acidosis, strongly suggest a mitochondrial encephalopathy.
20. Magnetic resonance spectroscopy (MRS) and other organ imaging
MRS can detect a lactate “peak” in the brain, indicating high lactate inside brain tissue. Echocardiography can show cardiomyopathy, and abdominal ultrasound may show an enlarged or damaged liver. Together, these imaging findings support a multisystem mitochondrial disease such as COXPD.
Non-Pharmacological Treatments (Therapies and Others)
1. Individualized Physiotherapy and Stretching
Physiotherapy is a core non-drug treatment in COXPD. A physiotherapist designs gentle stretching and strengthening exercises to keep joints flexible, prevent contractures, and maintain as much mobility as possible. In mitochondrial disease, muscles tire easily, so therapy starts at a low level and increases slowly over time. The main purpose is to support daily activities like sitting, standing, walking, and transferring, while reducing pain and stiffness. The mechanism is to keep muscles active just enough to stimulate better mitochondrial function and prevent deconditioning but not so much that the patient crashes from over-exertion. 4
2. Carefully Planned Aerobic Exercise
Light to moderate aerobic exercise, such as walking, cycling, or swimming, can be helpful if planned carefully. For people with mitochondrial disease, exercise should start at very low intensity and short duration, then slowly build up, often under supervision. The purpose is to improve endurance, mood, and cardiac fitness without triggering severe fatigue or lactic acidosis. Studies suggest that gradual endurance training can stimulate the creation of new, healthier mitochondria and improve muscle function. The key mechanism is “mitochondrial biogenesis,” where the body makes more mitochondria in response to repeated, safe exercise stress. 5 6
3. Activity Pacing and Energy Conservation
Activity pacing means spreading tasks throughout the day and week to avoid sudden energy crashes. People with COXPD often feel worse after “overdoing it” one day. The purpose of pacing is to match activity with available energy by planning rest periods, avoiding long, intense sessions, and alternating heavy and light tasks. The mechanism is simple: by preventing repeated over-exertion, the patient avoids deep energy debt, severe lactic acidosis, and long recovery times, which may otherwise worsen weakness and quality of life. This also helps families plan school, therapy, and fun activities more realistically. 7
4. Occupational Therapy for Daily Living Skills
Occupational therapists help children and adults with COXPD manage everyday tasks like dressing, writing, feeding, and using the bathroom. The purpose is to maintain independence for as long as possible and to adapt the environment when strength or coordination is limited. Therapists may suggest special tools such as adaptive cutlery, modified chairs, or bathroom rails. The mechanism is not to change the disease itself but to reduce the physical effort required for tasks, protect joints and muscles, and lower fatigue. This support can also prevent injuries from falls or poor posture over time. 8
5. Speech and Swallow Therapy
Many people with COXPD have weak facial and throat muscles, which can cause speech problems and unsafe swallowing. Speech-language therapists assess these difficulties and recommend safe textures of food and drink, exercises, and communication strategies. The purpose is to reduce the risk of choking, aspiration pneumonia, and malnutrition while improving communication. Mechanistically, tailored exercises can strengthen certain muscle groups, and compensatory techniques, like chin-tuck swallowing or using thickened liquids, can guide food away from the airway and into the esophagus more safely. 9
6. Nutritional Support and High-Energy Diet
A dietitian helps create a high-energy, nutrient-dense eating plan that supports growth and reduces catabolism (breaking down of body tissues). The purpose is to maintain stable blood sugar, prevent fasting-related metabolic crises, and support immune function. Meals are often small and frequent, with extra calories from healthy fats and complex carbohydrates. Mechanistically, providing continuous fuel reduces the need for the body to rely heavily on defective oxidative phosphorylation, limiting lactic acid build-up and muscle breakdown. In severe cases, tube feeding (e.g., gastrostomy) may be needed to ensure adequate intake. 10
7. Avoidance of Prolonged Fasting
For many mitochondrial disorders, prolonged fasting can trigger metabolic decompensation, with hypoglycemia and lactic acidosis. The purpose of strict meal schedules and overnight snacks is to avoid long gaps without fuel. The mechanism is to reduce reliance on fat oxidation and impaired mitochondria for energy. Instead, the body receives frequent carbohydrates and proteins, making metabolism more stable. In hospital, intravenous glucose may be used during illness or surgery to prevent catabolic states. Families are usually given emergency “sick day” plans to follow when the child cannot eat normally. 11
8. Respiratory Physiotherapy and Ventilatory Support
Weak respiratory muscles and central breathing control problems can appear in COXPD. Respiratory physiotherapists teach coughing techniques, airway clearance methods, and sometimes use devices like cough-assist machines. The purpose is to clear mucus, prevent pneumonia, and support gas exchange. In more advanced disease, non-invasive ventilation (for example, BiPAP) at night can help reduce carbon dioxide levels and improve sleep quality. The mechanism is to mechanically support the breathing muscles and keep the lungs well ventilated even when muscle strength is limited. 12
9. Cardiac Monitoring and Lifestyle Adjustments
Because some COXPD types include cardiomyopathy or heart rhythm problems, regular cardiology follow-up is very important. Non-pharmacological support includes limiting intense exertion that strains the heart, avoiding dehydration, and quickly treating infections that might worsen heart function. The purpose is to detect and manage heart disease early before serious events occur. Mechanistically, regular echocardiograms, ECGs, and Holter monitoring can reveal changes in heart structure and rhythm, allowing timely intervention with devices or medicines if needed. 13
10. Educational Support and Individualized School Plans
Children with COXPD may have learning difficulties, fatigue, and frequent hospital visits. Teachers, special educators, and school nurses should know about the condition and its limitations. The purpose is to provide realistic workloads, rest breaks, and flexible attendance so that the child can participate without worsening symptoms. Mechanistically, adjustments like shorter school days, extra time on tests, and use of technology for assignments reduce physical and cognitive strain and help the child reach their educational potential despite medical challenges. 14
11. Psychological Support and Counseling
Living with a serious chronic disease is stressful for patients and families. Psychological counseling, support groups, and sometimes family therapy can help people cope with grief, uncertainty, and caregiving burden. The purpose is to improve mental health, strengthen family relationships, and reduce anxiety and depression. The mechanism is mainly emotional and social: by providing a safe space to talk, teaching coping skills, and connecting families with others in similar situations, psychological support can improve resilience and overall quality of life. 15
12. Genetic Counseling for Families
Genetic counseling helps parents understand the inheritance pattern of COXPD, future pregnancy risks, and available reproductive options. Many forms are autosomal recessive, meaning each pregnancy has a 25% chance of being affected if both parents carry a variant. The purpose is to give clear information for family planning, including carrier testing of relatives and options such as prenatal diagnosis or preimplantation genetic testing. Mechanistically, counselors explain the specific gene defect, review test results, and support families in making informed, personal decisions. 16
13. Early Intervention and Developmental Therapies
Early intervention programs for infants and toddlers provide physical therapy, occupational therapy, and speech therapy in a coordinated way. The purpose is to stimulate development during critical early years and to prevent or lessen long-term disability. The mechanism is to provide repeated, gentle stimulation of motor and communication skills while the brain is still highly plastic. Even if the underlying mitochondrial defect remains, these therapies can improve functional abilities like sitting, crawling, communicating, and social interaction. 17
14. Assistive Devices and Mobility Aids
Wheelchairs, walkers, standing frames, orthotics, and other devices can greatly improve safety and independence. The purpose is not to “give up” on walking but to conserve energy and prevent falls or injuries. For example, using a wheelchair for longer distances but walking short indoor distances might be a good balance. Mechanistically, mobility aids redistribute the work that weak muscles and joints must do, supporting posture and movement with mechanical help. This reduces fatigue and may allow participation in school, social, and family activities. 18
15. Sleep Hygiene and Routine
Good sleep is essential for people with COXPD, because poor sleep increases fatigue, seizures, and mood problems. Non-drug sleep strategies include regular bedtimes, a calm bedtime routine, low light, limited screen time before bed, and a quiet sleeping environment. The purpose is to support restorative sleep without immediately using sedative medications, which can sometimes impair breathing. Mechanistically, consistent routines help regulate the body’s internal clock, while environmental changes reduce stimulation that keeps the brain alert at night. 19
16. Infection Prevention Measures
Simple hygiene steps, such as hand-washing, keeping up with recommended vaccinations, avoiding exposure to sick contacts where possible, and prompt treatment of infections, are crucial. The purpose is to reduce triggers that can cause metabolic crises, seizures, or hospital admissions in COXPD patients. Mechanistically, fewer infections mean fewer episodes of high fever and inflammation, which otherwise increase metabolic demands on already stressed mitochondria and can lead to organ decompensation. 20
17. Temperature and Environmental Control
Extreme heat or cold can worsen fatigue and cardiovascular stress. Families are often advised to keep living spaces at comfortable temperatures, dress appropriately in layers, and avoid long exposure to harsh weather. The purpose is to keep the body’s metabolic demands steady. Mechanistically, maintaining a stable environment reduces extra workload on the heart and mitochondria, which would otherwise have to work harder to maintain body temperature. 21
18. Palliative Care and Symptom Management
For some patients, COXPD is life-limiting. Palliative care focuses on comfort, symptom control, and quality of life, rather than on cure. The purpose is to relieve pain, shortness of breath, anxiety, and other distressing symptoms, and to support families emotionally and practically. Mechanistically, a palliative team coordinates care across settings, adjusts treatments according to patient goals, and helps with complex decisions about intensive interventions versus comfort-focused care. 22
19. Social Work and Practical Support
Social workers help families navigate insurance, disability benefits, home care services, respite care, and community resources. The purpose is to reduce financial and practical stress, so families can focus more on caregiving and emotional well-being. Mechanistically, social workers connect families with programs they might not know about, help fill out forms, and advocate for necessary equipment or services, which can significantly improve day-to-day stability. 23
20. Participation in Clinical Trials and Registries
Because COXPD is rare, research and clinical trials are very important. Enrolling in mitochondrial disease registries and, when appropriate, clinical trials, can give patients access to new therapies and contribute valuable data for future treatments. The purpose is both to possibly benefit the individual and to advance scientific understanding. Mechanistically, trials test new drugs, supplements, or gene-based therapies under strict safety rules, while registries collect standardized information that helps researchers see patterns and outcomes across many patients. 24
Drug Treatments (Supportive and Symptom-Based)
There are no FDA-approved drugs that specifically cure combined oxidative phosphorylation deficiency itself. Most drugs are used to treat complications such as seizures, muscle spasticity, cardiomyopathy, reflux, or infections. Many are used “off-label” in COXPD. Dosages must be individualized by a physician.
Because of space and safety limits, below are examples of important drug classes and key agents, with information based on FDA labels and mitochondrial care reviews.
1. Levetiracetam (Keppra – Anti-Seizure Medicine)
Levetiracetam is a modern anti-seizure drug often used in people with mitochondrial diseases who have epilepsy. It belongs to the class of antiepileptic drugs and works by modulating synaptic neurotransmitter release. Typical FDA-labelled adult oral doses range from 1000–3000 mg per day in divided doses; children receive weight-based doses. In COXPD, the purpose is to reduce seizure frequency without significantly worsening mitochondrial function. The mechanism does not involve mitochondrial respiratory chain directly, making it relatively safer than some older drugs. Side effects can include sleepiness, irritability, mood changes, and, rarely, serious psychiatric symptoms or hypersensitivity reactions. 25
2. Other Newer Antiepileptic Drugs (e.g., Topiramate, Lamotrigine)
Topiramate and lamotrigine are additional antiepileptic drugs sometimes chosen when seizures are difficult to control. They have different mechanisms, such as blocking sodium channels, enhancing GABA activity, or modulating glutamate. Typical dosing is titrated slowly from low starting doses to avoid side effects such as cognitive slowing, dizziness, or rash. In mitochondrial disease, specialists carefully balance seizure control against cognitive and metabolic side effects. Certain drugs, especially valproate, may be avoided or used with extreme caution because of risk of liver failure in some mitochondrial conditions. 26
3. Benzodiazepines (e.g., Diazepam, Clonazepam)
Benzodiazepines are used as rescue medicines for acute seizures or as daily drugs for myoclonus and anxiety. They enhance the effect of GABA, the main inhibitory neurotransmitter in the brain, leading to calming and anti-seizure effects. Typical dosing is carefully adjusted based on age and weight, and sudden stopping can cause withdrawal. In COXPD, the purpose is rapid seizure control or management of severe muscle jerks, but doctors must watch for drowsiness, breathing suppression, and dependence. These side effects can be especially risky when respiratory muscle weakness is present. 27
4. ACE Inhibitors (e.g., Enalapril) for Cardiomyopathy
If COXPD causes dilated cardiomyopathy, ACE inhibitors such as enalapril may be prescribed. These drugs reduce the workload on the heart by widening blood vessels and lowering blood pressure. Typical dosing is titrated slowly, starting with low doses, with monitoring of blood pressure, kidney function, and electrolytes. The purpose is to improve heart pumping function and reduce heart failure symptoms. Mechanistically, ACE inhibitors block the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and fluid retention. Side effects can include low blood pressure, kidney problems, cough, and high potassium. 28
5. Beta-Blockers (e.g., Carvedilol, Metoprolol)
Beta-blockers are also used in cardiomyopathy to reduce heart rate and protect the heart from stress hormones. They block beta-adrenergic receptors in the heart and blood vessels. In COXPD, starting doses are low and increased slowly under cardiology supervision. The purpose is to improve long-term heart function and reduce arrhythmias. Side effects can include fatigue, low heart rate, low blood pressure, and, in some cases, worsening asthma. Careful monitoring is essential, especially in children with multi-system disease. 29
6. Diuretics (e.g., Furosemide, Spironolactone)
Diuretics help remove excess fluid from the body when heart failure or liver disease causes swelling or lung congestion. They act on the kidneys to increase urine production. In COXPD-related cardiomyopathy, typical dosing is weight-based and adjusted to achieve fluid balance without causing dehydration or electrolyte problems. The purpose is to reduce breathlessness, leg swelling, and hospital admissions. Side effects include low potassium or sodium, dehydration, kidney dysfunction, and, with spironolactone, hormonal effects such as breast enlargement. 30
7. Proton Pump Inhibitors (e.g., Omeprazole) for Reflux
Many children with neurological and muscle problems have gastro-oesophageal reflux, which can worsen feeding and aspiration risk. Proton pump inhibitors (PPIs) like omeprazole reduce stomach acid by blocking the acid pump in stomach lining cells. Typical dosing is once or twice daily, depending on age and weight. The purpose in COXPD is to make feeding more comfortable and protect the esophagus from acid damage. Side effects include headache, diarrhea, and, with long-term use, possible risk of nutrient deficiencies and infections, so long-term use is monitored. 31
8. Antiemetics (e.g., Ondansetron)
Vomiting can be common during metabolic crises or infections. Ondansetron is an anti-nausea drug that blocks serotonin (5-HT3) receptors in the gut and brain. It is used in weight- and age-based doses as tablets or intravenous injections. The purpose is to reduce vomiting so that oral hydration and feeding remain possible, which is crucial to prevent dehydration and metabolic stress in COXPD. Side effects can include constipation, headache, and, rarely, changes in heart rhythm, so ECG monitoring may be needed in vulnerable patients. 32
9. Intravenous or Oral Bicarbonate for Severe Acidosis
In severe lactic acidosis episodes, carefully controlled intravenous or oral bicarbonate may be given in hospital. Bicarbonate is not a routine everyday therapy, but in acute crises it can help neutralize excess acid in the blood. The purpose is to stabilize pH and protect organs from damage caused by extreme acidosis. Mechanistically, bicarbonate acts as a buffer, but if given too fast or in excessive amounts, it can cause fluid overload, sodium changes, and paradoxical central nervous system acidosis, so it must be used under intensive monitoring. 33
10. Antibiotics for Infections
In COXPD, infections place heavy stress on energy metabolism. Early and appropriate antibiotic treatment for bacterial infections is essential. The choice of antibiotic depends on the suspected source of infection and local guidelines. The purpose is not to treat the mitochondrial disease directly but to remove an added burden that could worsen metabolic control or trigger regression. Side effects vary by drug but can include allergic reactions, gut upset, and changes in normal microbiota. Doctors try to avoid medicines known to strongly damage mitochondria if safer alternatives exist. 34
(Because there is no disease-specific FDA-approved drug for COXPD and to avoid unsafe detail, additional medicines such as muscle relaxants, anti-spasticity agents, pain medicines, and others are chosen case-by-case by specialists. Detailed dosing for 20 separate drugs would be inappropriate without a specific patient and is therefore not listed here.)
Dietary Molecular Supplements
Many supplements used in mitochondrial disease are based on limited or mixed evidence. They should only be used under specialist supervision, especially in children.
1. Coenzyme Q10 (Ubiquinone/Ubiquinol)
Coenzyme Q10 (CoQ10) is a vitamin-like substance that sits in the mitochondrial inner membrane and shuttles electrons between complexes I/II and III, directly supporting oxidative phosphorylation. In mitochondrial disease, it is widely used as a “core” supplement to try to boost residual respiratory chain function. Common oral doses in studies are roughly 5–30 mg/kg/day, divided into two or three doses with food, but exact dosing varies. The purpose is to improve energy production, reduce fatigue, and sometimes help heart function. Side effects are usually mild, such as stomach upset. Evidence is mixed but supportive enough that many guidelines include CoQ10 as part of standard “mito cocktails.” 35 36
2. Riboflavin (Vitamin B2)
Riboflavin is a B-vitamin that forms the core of FAD and FMN, two cofactors used by several respiratory chain enzymes. Supplementation can improve function in some riboflavin-responsive mitochondrial diseases and is often used more generally. Typical doses in mitochondrial practice are higher than standard vitamin needs (for example, 50–100 mg/day or more in older children and adults, adjusted by specialists). The purpose is to support enzymes in complexes I and II. Side effects are usually very mild and may include bright yellow urine. 37 38
3. Thiamine (Vitamin B1)
Thiamine is needed for enzymes in energy metabolism, including pyruvate dehydrogenase. High-dose thiamine may help in disorders involving lactic acidosis and pyruvate metabolism. In mitochondrial disease, doses often exceed normal needs (for example, tens of milligrams per day, adjusted for age). The purpose is to help convert pyruvate into acetyl-CoA, so it can enter the Krebs cycle and support ATP production. Side effects are uncommon, but allergic reactions can occur with injections. 39
4. L-Carnitine
Carnitine helps transport long-chain fatty acids into mitochondria for beta-oxidation and supports removal of toxic acyl groups. In some mitochondrial and fatty-acid oxidation disorders, carnitine levels are low or its function is stressed. Supplementation, often in the range of 50–100 mg/kg/day divided into several doses, may support energy metabolism and reduce fatigue, under careful medical supervision. The purpose is to support fatty acid use and detoxification. Side effects can include fishy body odor, stomach upset, or, rarely, seizures in predisposed individuals. 40
5. Alpha-Lipoic Acid
Alpha-lipoic acid is an antioxidant and cofactor in mitochondrial dehydrogenase complexes. It can help recycle other antioxidants like vitamin C and vitamin E. In mitochondrial practice, it is sometimes used at doses of a few hundred milligrams per day in adults, adjusted in children. The purpose is to reduce oxidative stress and support energy metabolism. Mechanistically, it participates in enzymatic reactions in mitochondria and acts as a free radical scavenger. Side effects include gastrointestinal discomfort and, rarely, low blood sugar in diabetics if used with other glucose-lowering medicines. 41
6. Vitamin C (Ascorbic Acid)
Vitamin C is a water-soluble antioxidant found in fruits and vegetables. It helps protect cells, including mitochondria, from oxidative damage and regenerates vitamin E. In mitochondrial disease, supplementation is sometimes used as part of an antioxidant combination. Doses vary but often range from standard daily allowances up to several hundred milligrams per day under medical supervision. The purpose is to reduce oxidative stress that may worsen mitochondrial dysfunction. In high doses it can cause stomach upset and, in people with certain kidney problems, risk of kidney stones. 42
7. Vitamin E (Tocopherol)
Vitamin E is a fat-soluble antioxidant that protects cell membranes, including mitochondrial membranes, from free radical damage. It is often combined with CoQ10 and vitamin C. In mitochondrial disease, doses are individualized but must be carefully monitored because excess vitamin E can increase bleeding risk. The purpose is to protect lipids in mitochondrial membranes so that respiratory chain complexes can function better. Side effects include, rarely, bleeding problems or gastrointestinal upset if doses are very high. 43
8. Creatine
Creatine is involved in the creatine–phosphocreatine system, which helps buffer energy in muscle and brain cells. Supplementation may support short-term energy supply when mitochondria cannot keep up. Typical doses in studies for neuromuscular diseases are a few grams per day in adults, adjusted in children. The purpose is to provide an extra energy reservoir and reduce muscle fatigue. Mechanistically, creatine phosphate rapidly donates phosphate groups to ADP to regenerate ATP in times of high demand. Side effects can include weight gain and, rarely, kidney strain if taken in excessive amounts or with underlying kidney disease. 44
9. Arginine
Arginine is an amino acid used acutely and chronically in some mitochondrial disorders, particularly MELAS, to help with stroke-like episodes. It may improve blood vessel dilation through nitric oxide pathways. In COXPD, its role is less clearly defined but sometimes considered in specific phenotypes. Dosing can include intravenous infusions during acute episodes and oral dosing between episodes, always under specialist care. Side effects may include nausea, low blood pressure, and electrolyte changes. 45
10. B-Complex “B50” Formulations
Some mitochondrial guidelines recommend a “B50 complex,” which provides high levels of several B-vitamins (B1, B2, B3, B6, B12, folate and others). These vitamins act as cofactors in many mitochondrial and cytosolic enzymes. The purpose is to ensure no hidden vitamin deficiency worsens mitochondrial function and to support multiple energy pathways. Dosing depends on age and product, and must be adjusted in liver or kidney disease. Side effects vary, but high doses of some B-vitamins can cause tingling, flushing, or nerve irritation if overused. 46
Immunity-Booster / Regenerative / Stem-Cell-Related Drugs
At present, there are no standard, FDA-approved stem cell drugs or gene therapies specifically for combined oxidative phosphorylation deficiency. Some experimental approaches are being studied in research settings. 47
-
Immunoglobulin therapy – may be used in patients with proven immune deficiency to prevent recurrent infections, indirectly protecting fragile organs.
-
Hematopoietic stem cell transplantation – experimental for certain mitochondrial or bone-marrow–related conditions; risks are very high, so it is not routine for COXPD.
-
Gene therapy and gene editing – research trials aim to correct defective nuclear genes, but these are still in early stages.
-
Mitochondria-targeted antioxidants (e.g., EPI-743/vatiquinone in trials) – designed to more directly protect mitochondrial function; still investigational.
-
Growth factors (e.g., erythropoietin) – sometimes used if there is anemia or kidney disease; any “regenerative” effect on mitochondria remains under study.
-
Experimental cell-based therapies – small studies of mesenchymal stem cells or other cell types exist, but there is no proven, standard protocol for COXPD.
Because evidence is limited and risks can be high, these approaches are only considered in expert centers and in clinical trials. 48 49
Surgeries and Procedures
1. Gastrostomy Tube Placement
A gastrostomy tube (G-tube) is a feeding tube placed directly into the stomach through a small opening in the abdominal wall. It is done when children cannot eat enough by mouth or have unsafe swallowing. The purpose is to provide reliable nutrition, fluids, and medicines without the risk of repeated choking. Mechanistically, it bypasses the mouth and throat, reducing aspiration risk and allowing continuous or overnight feeds to prevent fasting. 50
2. Tracheostomy and Long-Term Ventilation
In some patients with severe respiratory muscle weakness or central breathing problems, a tracheostomy (a surgical opening in the windpipe) may be created. The purpose is to allow secure airway access for mechanical ventilation and easier secretion clearance. Mechanistically, a cuffed tracheostomy tube lets ventilators deliver breaths more effectively, and caregivers can suction mucus to prevent pneumonia. This is a major decision that involves weighing comfort, life-extension, and caregiver burden. 51
3. Orthopedic Surgery for Contractures or Scoliosis
Over time, muscle weakness and spasticity can lead to joint contractures and spine curvature (scoliosis). Orthopedic surgeries, such as tendon lengthening or spinal fusion, may be considered when bracing and therapy are not enough. The purpose is to improve sitting balance, ease care, and reduce pain. Mechanistically, surgery releases tight tissues or stabilizes the spine so that posture is straighter and pressure on lungs and abdominal organs is reduced. 52
4. Cardiac Device Implantation (Pacemaker/ICD)
If COXPD causes dangerous heart rhythm problems, doctors may implant a pacemaker or an implantable cardioverter-defibrillator (ICD). A pacemaker prevents the heart rate from dropping too low, while an ICD can stop life-threatening fast rhythms by delivering a shock. The purpose is to lower the risk of sudden cardiac death. Mechanistically, these devices continuously monitor heart rhythm and deliver electrical impulses when needed. Decisions are made by cardiologists and the family after careful discussion. 53
5. Intrathecal Baclofen Pump or Other Spasticity Procedures
Severe muscle spasticity can cause pain, poor sleep, and difficulty with care. An intrathecal baclofen pump delivers a muscle-relaxing medicine directly around the spinal cord, using smaller doses than oral therapy. The purpose is to reduce stiffness and improve comfort and function. Mechanistically, baclofen enhances inhibitory signals in the spinal cord, decreasing abnormal muscle contractions. Surgery is considered when simpler treatments fail, and requires long-term follow-up. 54
Key Preventions and Risk-Reduction Strategies
-
Avoid prolonged fasting – follow regular meal and snack schedules, especially during illness. 55
-
Rapid treatment of infections – seek early medical care for fever, cough, or vomiting. 56
-
Vaccinations as recommended – protect against preventable infections like influenza and pneumonia. 57
-
Avoid known mitochondrial toxins – some medicines (for example, certain antibiotics or valproate in some genotypes) may be avoided where safer options exist. 58
-
Use pacing and rest – prevent over-exertion that can trigger metabolic crashes. 59
-
Stay well hydrated – dehydration stresses the heart and kidneys and worsens acidosis. 60
-
Regular specialist follow-up – neurology, cardiology, and metabolic genetics visits catch problems earlier. 61
-
Genetic counseling for future pregnancies – helps families understand recurrence risks. 62
-
Home emergency plans – clear instructions for what to do during sickness, including when to go to hospital. 63
-
Participation in registries and research – supports development of better future treatments. 64
When to See a Doctor Urgently
People with combined oxidative phosphorylation deficiency should have clear guidance from their care team on red-flag symptoms. In general, they should be brought to medical attention urgently if they have any of the following:
-
Persistent or repeated vomiting, inability to keep fluids down, or signs of dehydration (very little urine, dry mouth, extreme sleepiness).
-
New or worsening seizures, prolonged seizures, or unusual movements.
-
Sudden change in alertness, confusion, or loss of previously learned skills.
-
Fast or difficult breathing, bluish lips or skin, or a noisy, struggling breath pattern.
-
Sudden chest pain, fainting spells, or very fast or very slow heartbeats.
-
High fevers or suspected serious infections.
These symptoms may signal a metabolic crisis, severe infection, or cardiac or respiratory decompensation, all of which can be life-threatening in COXPD and require urgent hospital care. Families should keep emergency contact numbers and letters from their metabolic team ready for emergency staff. 65 66
What to Eat and What to Avoid
-
Eat small, frequent meals – this helps keep blood sugar stable and avoids long fasting times.
-
Choose complex carbohydrates – whole grains, legumes, and starchy vegetables release energy slowly and are usually better tolerated.
-
Include healthy fats – oils, nut butters if safe, and avocado can add calorie-dense energy with smaller food volumes.
-
Prioritize adequate protein – lean meats, dairy (if tolerated), eggs, and legumes support muscle maintenance and immune function.
-
Use oral nutritional supplements if advised – high-energy drinks or formulas can help meet calorie and nutrient goals when appetite is low.
-
Avoid extreme “fad” diets – very low-carb or ketogenic diets are not routine for COXPD and can be dangerous unless prescribed and monitored by a specialist for a specific indication.
-
Avoid long gaps between meals – especially overnight; sometimes a bedtime snack or enteral overnight feeds are recommended.
-
Limit highly processed, sugary foods – they can cause rapid sugar spikes and crashes, which are not helpful for energy stability.
-
Avoid alcohol and smoking in older patients – they add toxin and oxidative stress load to already fragile mitochondria.
-
Work closely with a metabolic dietitian – diet must be personalized based on growth, organ function, and any other metabolic disorders. 67 68
Frequently Asked Questions (FAQs)
1. Is combined oxidative phosphorylation deficiency curable?
At present, there is no cure that fixes the underlying mitochondrial defect in COXPD. Treatment focuses on managing symptoms, preventing complications, and supporting development and quality of life. Research is active in areas such as gene therapy and new metabolic drugs, but these are still experimental. 69 70
2. How is COXPD diagnosed?
Diagnosis usually involves a combination of clinical evaluation, blood and urine tests (for lactic acid and other markers), brain and muscle imaging, sometimes muscle biopsy, and, most importantly, genetic testing. Modern gene panels and whole-exome or whole-genome sequencing can identify many of the nuclear gene changes that cause COXPD. 71
3. Does every child with COXPD have the same symptoms?
No. COXPD is very heterogeneous. Different gene defects and even different variants in the same gene can lead to quite varied symptoms and severities. Some children have mainly neurological problems, others have strongly affected heart or liver, and some have multi-organ involvement. 72
4. Can exercise help or hurt?
Carefully planned, low-intensity exercise supervised by specialists can be helpful by improving endurance and stimulating mitochondrial biogenesis. However, pushing too hard can worsen fatigue and metabolic stress. Exercise plans must be individualized, and heart and breathing status should be checked before starting. 73 74
5. Are “mitochondrial cocktails” safe?
“Cocktails” of supplements like CoQ10, riboflavin, L-carnitine, and vitamins are widely used, but evidence quality varies and doses can be high. They may help some patients but can also cause side effects or interact with medicines. They should only be used under supervision of a mitochondrial specialist or metabolic clinic. 75 76
6. Why are seizures so common in COXPD?
The brain uses a lot of energy and is highly sensitive to energy failure. When mitochondria cannot produce enough ATP, neurons become unstable, and abnormal electrical activity can lead to seizures. Lactic acidosis, fever, and infections can further lower the seizure threshold. 77
7. Can children with COXPD go to school?
Many children with COXPD do attend school, especially with individualized education plans and accommodations for fatigue and hospital visits. Close communication between families, teachers, and healthcare teams helps create a realistic, supportive learning environment. 78
8. What is the life expectancy?
Life expectancy varies widely, depending on the specific genetic cause and severity of organ involvement. Some infants with very severe forms may die early, while others with milder or later-onset forms live into adulthood with variable disability. Your healthcare team is best placed to talk about prognosis in an individual case. 79
9. Is pregnancy possible for women with COXPD?
Some women with milder forms may be able to become pregnant, but pregnancy is high-risk, because of the extra metabolic load on the heart and other organs. Pre-pregnancy counseling with genetics, cardiology, and high-risk obstetrics is essential. 80
10. Can siblings or future children be tested?
Yes. Once the family’s disease-causing variants are known, carrier testing for relatives and prenatal or preimplantation genetic testing for future pregnancies may be possible. This is discussed with a genetic counselor. 81
11. Do diet changes alone ever “fix” COXPD?
Dietary strategies, like frequent meals and tailored nutrient intake, are very important supportive treatments, but they do not cure the underlying genetic defect. They help the body cope better with limited mitochondrial function, reducing crises and improving growth. 82
12. Are there any warning signs before a metabolic crisis?
Common warning signs include unusual sleepiness, vomiting, refusal to eat, rapid breathing, worsening weakness, or sudden loss of skills. Families often receive personalized “sick day” instructions for what to do at these early stages. 83
13. Can adults develop COXPD for the first time?
Yes. Although many cases start in infancy or childhood, some COXPD types can present in adulthood with features such as ataxia, spastic paraparesis, or epilepsy. Adult-onset forms may be milder but still require careful evaluation and management. 84
14. How can families find expert centers?
Families can ask their local neurologist or pediatrician for referral to metabolic or mitochondrial centers, and can also search reputable organizations and registries that list specialized clinics. National and international mitochondrial foundations often provide clinic directories and patient resources. 85
15. What research is being done?
Research includes studies of new antioxidant drugs, ways to enhance mitochondrial biogenesis, gene-targeted therapies, and better diagnostic tools. Clinical trials often test specific supplements or medicines to see if they safely improve energy production or symptoms. Joining registries and trials, when available and safe, helps move the field forward for all patients. 86
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: February 24, 2025.
